Latest filing published 10 Sept 2026 for Iovance Biotherapeutics, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Igor Bilinsky (senior executive) discloses dealings in 2 companies, chiefly Iovance Biotherapeutics, Inc. and Ignyta, Inc. The record holds 31 filings, for trades running from 7 January 2016 to 8 September 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 10 September 2026, the filings show an option exercise in Iovance Biotherapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 31 declarations